Loading
TPST-2003 is a CAR-T cell treatment, made from a patient's own immune cells, from Tempest Therapeutics. It targets two markers and is being tested in multiple myeloma that has come back.
TPST-2003 is an autologous CD19 and BCMA CAR-T therapy whose rights Tempest Therapeutics acquired in February 2026. Tempest describes it as in clinical development for relapsed or refractory multiple myeloma and for POEMS syndrome, a rare plasma cell disorder; the filing does not state the phase.
1.TPST-2003 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TPST-2003" OR ABSTRACT:"TPST-2003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TPST-2003, not a curated reading list.
Shares Tempest Therapeutics, BCMA, CD19 and the tag pipeline.
Shares CD19, CAR-T cell therapy and the tag pipeline.
Shares BCMA and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares BCMA, CAR-T cell therapy and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares BCMA and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/